COMMUNIQUÉS West-GlobeNewswire

RadNet Announces Pricing and Upsizing of its Previously Announced Term Loan and Revolving Credit Facility Refinancing Transaction
11/04/2024
LOS ANGELES, April 11, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today announced that it has [...]
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
11/04/2024
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve [...]
Novartis tender offer for MorphoSys AG commences
11/04/2024
Basel, April 11, 2024 – Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG (“MorphoSys”), [...]
Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024
11/04/2024
Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer Data presented at AACR 2024 shows MACO-355 is highly potent in [...]
Orion publishes Interim Report for January–March 2024 and holds a webcast on 25 April 2024
11/04/2024
ORION CORPORATION PRESS RELEASE 11 APRIL 2024 at 9.30 EEST Orion publishes Interim Report for January–March 2024 and holds a webcast on 25 April 2024 Orion will publish Interim Report for January–March 2024 on Thursday [...]
ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast
11/04/2024
EINDHOVEN, the Netherlands, April 11, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, [...]
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
11/04/2024
The Elecsys® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly and Company Once approved, the test will aid healthcare providers in identifying amyloid [...]
Record revenue of €209 million in first quarter reflecting 15% topline growth
11/04/2024
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagron, the leading [...]
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
11/04/2024
Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its [...]
Idorsia takes steps to address short-term liquidity needs
11/04/2024
Ad hoc announcement pursuant to Art. 53 LR A bondholders meeting is expected to take place on April 30, 2024, to request the right to repay the bonds maturing in 2024, fully or partially in shares of Idorsia Main [...]
CARBIOS announces fiscal-year 2023 financial results and confirms 2024 calendar for industrial and commercial roll-out
11/04/2024
CARBIOS Group’s solid financial structure: cash position of €192 million on December 31, 2023 Construction progress of world’s first PET 1 biorecycling plant in France: in line with delivery targets for customers in [...]
CARBIOS présente ses résultats annuels 2023 et confirme le calendrier 2024 de son déploiement industriel et commercial
11/04/2024
Solide structure financière du Groupe CARBIOS : position de trésorerie de 192 millions d’euros au 31 décembre 2023 Avancée de la construction, en France, de la première usine au monde de biorecyclage du PET 1 : [...]
2024 Canada Gairdner Awards Recognize World-Renowned Scientists for Transformative Contributions to Research Impacting Human Health
11/04/2024
TORONTO, April 11, 2024 (GLOBE NEWSWIRE) -- The Gairdner Foundation is pleased to announce the 2024 Canada Gairdner Award laureates, recognizing some of the world’s most significant biomedical and global health research [...]
LES PRIX CANADA GAIRDNER 2024 RECONNAISSENT DES SCIENTIFIQUES DE RENOMMÉE MONDIALE POUR DES CONTRIBUTIONS TRANSFORMATRICES À LA RECHERCHE AYANT UN IMPACT SUR LA SANTÉ HUMAINE
11/04/2024
TORONTO, 11 avr. 2024 (GLOBE NEWSWIRE) -- La Fondation Gairdner est heureuse d’annoncer les lauréats des Prix Canada Gairdner 2024, reconnaissant certaines des recherches et des découvertes biomédicales et en santé [...]
AVITA Medical Updates Expected First Quarter 2024 Revenue
10/04/2024
VALENCIA, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]
BrightSpring Health Services Specialty Pharmacy Onco360® Selected as National Pharmacy Partner for Voydeya®
10/04/2024
LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) announced today that its company Onco360 ® , a leading independent [...]
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
10/04/2024
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Cellectis publie une nouvelle approche d'édition intronique pour le traitement des maladies métaboliques congénitales par des cellules souches hématopoïétiques modifiées
10/04/2024
NEW YORK, 10 avr. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN ® pour développer [...]
PharmAla Announces Private Placement and Concurrent Debt Settlement
10/04/2024
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, [...]

Pages